v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
OPERATING EXPENSES:        
Research and development $ 29,175 $ 30,325 $ 55,655 $ 61,205
General and administrative 23,197 12,608 39,621 31,344
Total operating expenses 52,372 42,933 95,276 92,549
Loss from operations: (52,372) (42,933) (95,276) (92,549)
OTHER (EXPENSE) INCOME, NET:        
Fair value change of warrant liabilities (205,577) (2,540) (74,661) 16,920
Interest income 3,744 1,898 6,163 4,284
Benefit from R&D tax credit 2,583 4,287 5,060 12,735
Interest expense (1,483) (1,151) (2,948) (2,275)
Foreign exchange (losses) gains (904) 2,349 (1,640) 4,482
Other income (expense) 546 (176) 1,030 627
Total other (expense) income, net (201,091) 4,667 (66,996) 36,773
Loss before income taxes (253,463) (38,266) (162,272) (55,776)
Income tax expense (331) (137) (320) (491)
Net loss $ (253,794) $ (38,403) $ (162,592) $ (56,267)
Net loss per share attributable to ordinary shareholders: basic (in dollars per share) $ (1.88) $ (0.41) $ (1.33) $ (0.62)
Net loss per share attributable to ordinary shareholders: diluted (in dollars per share) $ (1.88) $ (0.41) $ (1.33) $ (0.62)
Weighted average ordinary shares outstanding: basic (in shares) 135,039,810 93,341,594 122,679,123 91,278,385
Weighted average ordinary shares outstanding: diluted (in shares) 135,039,810 93,341,594 122,679,123 91,278,385
Other comprehensive income:        
Foreign exchange translation adjustment $ 54 $ 1,729 $ 48 $ 1,612
Comprehensive loss $ (253,740) $ (36,674) $ (162,544) $ (54,655)